Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is in the pharmaceutical business, mainly dealing in active pharmaceutical ingredients, pharmaceutical formulations, surgical products, and veterinary supplements, operating in domestic and export markets. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceutical, oncology, surgical, and veterinary. The Company has manufactured and exported approximately 250 formulations and specializes in manufacturing tailor-made formulations. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/ anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, antiviral, antifungal, skeletal muscle relaxant, and anthelmintic drugs, excipients, topical steroids, corticosteroids, and enzymes. It has a global presence in Asia & Pacific, Africa, the Commonwealth of Independent States, America, and the Middle East.
Vaishali Pharma Quarterly Result Highlights
- Vaishali Pharma reported revenue of ₹28.19 crore in Mar 2026, compared with ₹25.54 crore in Dec 2025, representing an increase of 10.38% on a quarter-on-quarter (QoQ) basis.
- Vaishali Pharma reported an operating profit of ₹0.18 crore in Mar 2026, compared with ₹1.82 crore in Dec 2025, representing a decrease of 90.11% on a quarter-on-quarter (QoQ) basis.
- Vaishali Pharma reported a profit of ₹0.29 crore in Mar 2026, compared with ₹1.30 crore in Dec 2025, reflecting a decrease of 77.69% on a QoQ basis.